Abstract
Background Fresh frozen plasma is a critical substitute therapy in management of bleeding. Increased risk of venous thrombosis has been described to be associated with high plasma levels of several coagulation factors.
Methodology This study was a longitudinal study involving time series analysis of fresh frozen plasma stored at -18°C for five weeks. A sample of 180 ml plasma was obtained from the blood centrifuged at 4000rpm which was aliquoted into three parts each containing 60ml. The first aliquot was used to assess the changes in coagulation factors in FFP at baseline during the first week of sample collection, the second aliquot was used to assess the changes in coagulation factors in FFP storage at -18°C temp after three weeks of storage, the third aliquot was used to assess the changes in coagulation factors in FFP storage at -18°C temp after five weeks of storage. Coagulation factor analysis was performed using Erba Mannheim ECL 105 coagulation analyzer, India factor results recorded. Thawing for subsequent coagulation factor analysis and serial testing of stored cryoprecipitate and fresh frozen plasma was done using Stericox Plasma Thawing Bath at 37°C, for 45 mins before before analyzing the samples. Standard storage conditions for the aliquots were monitored and maintained to ensure homogeneity.
Results The findings showed significant changes in the coagulation factors in FFP during storage at -18 for a period to five weeks with chi-square value of 216.000 and asymptomatic significance value (p-value) <0.0001* less than the standard alpha 0.05.
Conclusion There was a constant decrease of coagulation factors in fresh frozen plasma during storage at -18°C for 5 weeks at Kisii Teaching and Referral Hospital, Kisii County.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Baraton University ethical review committee-(clearance reference number: UEAB/ISERC/02/05/2022) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data analysis produced in the present work are contained in the manuscript
